Top

Published in:

Open Access 01-12-2022 | Research

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals

Authors: C. Pascoal, I. Ferreira, C. Teixeira, E. Almeida, A. Slade, S. Brasil, R. Francisco, A. N. Ligezka, E. Morava, H. Plotkin, J. Jaeken, P. A. Videira, L. Barros, V. dos Reis Ferreira

Published in: Orphanet Journal of Rare Diseases | Issue 1/2022

Abstract

Background

Congenital disorders of glycosylation (CDG) are a growing group of rare genetic disorders. The most common CDG is phosphomannomutase 2 (PMM2)-CDG which often has a severe clinical presentation and life-limiting consequences. There are no approved therapies for this condition. Also, there are no validated disease-specific quality of life (QoL) scales to assess the heterogeneous clinical burden of PMM2-CDG which presents a challenge for the assessment of the disease severity and the impact of a certain treatment on the course of the disease.

Aim and methods

This study aimed to identify the most impactful clinical signs and symptoms of PMM2-CDG, and specific patient and observer reported outcome measures (PROMs and ObsROMs, respectively) that can adequately measure such impact on patients’ QoL. The most burdensome signs and symptoms were identified through input from the CDG community using a survey targeting PMM2-CDG families and experts, followed by family interviews to understand the real burden of these symptoms in daily life. The list of signs and symptoms was then verified and refined by patient representatives and medical experts in the field. Finally, a literature search for PROMs and ObsROMs used in other rare or common diseases with similar signs and symptoms to those of PMM2-CDG was performed.

Results

Twenty-four signs/symptoms were identified as the most impactful throughout PMM2-CDG patients’ lifetime. We found 239 articles that included tools to measure those community-selected PMM2-CDG symptoms. Among them, we identified 80 QoL scales that address those signs and symptoms and, subsequently, their psychometric quality was analysed. These scales could be applied directly to the PMM2-CDG population or adapted to create the first PMM2-CDG-specific QoL questionnaire.

Conclusion

Identifying the impactful clinical manifestations of PMM2-CDG, along with the collection of PROMs/ObsROMs assessing QoL using a creative and community-centric methodology are the first step towards the development of a new, tailored, and specific PMM2-CDG QoL questionnaire. These findings can be used to fill a gap in PMM2-CDG clinical development. Importantly, this methodology is transferable to other CDG and rare diseases with multiple signs and symptoms.

Available only for authorised users

WHOQOL - Measuring Quality of Life| The World Health Organization n.d. https://www.who.int/tools/whoqol (accessed June 24, 2022).

GH Guyatt DH Feeny DL Patrick 1993 Measuring health-related quality of life Ann Intern Med 118 622 629 https://doi.org/10.7326/0003-4819-118-8-199304150-00009CrossRefPubMed

M Vries De R Ouwendijk AG Kessels MW Haan De K Flobbe MGM Hunink 2005 Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease J Vasc Surg 41 261 268 https://doi.org/10.1016/J.JVS.2004.11.022CrossRefPubMed

WR Lenderking M Anatchkova R Pokrzywinski A Skalicky ML Martin H Gelhorn 2021 Measuring health-related quality of life in patients with rare disease J Patient-Reported Outcomes 5 1 7 https://doi.org/10.1186/S41687-021-00336-8/METRICSCrossRef

A Whittal M Meregaglia E Nicod 2021 The use of patient-reported outcome measures in rare diseases and implications for health technology assessment Patient 14 485 503 https://doi.org/10.1007/S40271-020-00493-WCrossRefPubMedPubMedCentral

C Pascoal S Brasil R Francisco D Marques-Da-Silva A Rafalko J Jaeken 2018 Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review Orphanet J Rare Dis https://doi.org/10.1186/S13023-018-0953-9CrossRefPubMedPubMedCentral

PR Deshpande S Rajan BL Sudeepthi CPA Nazir 2011 Patient-reported outcomes: a new era in clinical research Perspect Clin Res 2 137 https://doi.org/10.4103/2229-3485.86879CrossRefPubMedPubMedCentral

S Bele A Chugh B Mohamed L Teela L Haverman MJ Santana 2020 Patient-reported outcome measures in routine pediatric clinical care: a systematic review Front Pediatr 8 364 https://doi.org/10.3389/FPED.2020.00364/BIBTEXCrossRefPubMedPubMedCentral

Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. 2016.

10.

Administration F and D. Patient-reported outcome measures: use in medical product development to support labeling claims n.d. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (accessed February 3, 2022).

11.

P Lipiński A Tylki-Szymańska 2021 Congenital disorders of glycosylation: what clinicians need to know? Front Pediatr 9 926 https://doi.org/10.3389/FPED.2021.715151/BIBTEXCrossRef

12.

IJ Chang M He CT Lam 2018 Congenital disorders of glycosylation Ann Transl Med 6 477 https://doi.org/10.21037/ATM.2018.10.45CrossRefPubMedPubMedCentral

13.

R Altassan R Péanne J Jaeken R Barone M Bidet D Borgel 2019 International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: diagnosis, treatment and follow up J Inherit Metab Dis 42 5 28 https://doi.org/10.1002/JIMD.12024CrossRefPubMed

14.

Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG | Glycomine n.d. https://www.glycomine.com/glycomine-announces-first-dosing-in-phase-1-clinical-study-of-glm101-a-potential-treatment-for-pmm2-cdg/ (accessed February 15, 2022).

15.

AF Martínez-Monseny M Bolasell L Callejón-Póo D Cuadras V Freniche DC Itzep 2019 AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG) Ann Neurol 85 740 751 https://doi.org/10.1002/ANA.25457CrossRefPubMed

16.

AN Ligezka S Radenkovic M Saraswat K Garapati W Ranatunga W Krzysciak 2021 Sorbitol Is a severity biomarker for PMM2-CDG with therapeutic implications Ann Neurol 90 887 900 https://doi.org/10.1002/ANA.26245CrossRefPubMed

17.

KE Flynn 2021 PROM proposal: analyzing proxy reports of patient-reported outcome measures Circ Cardiovasc Qual Outcomes 14 e008529https://doi.org/10.1161/CIRCOUTCOMES.121.008529CrossRefPubMed

18.

K Kroenke TE Stump PO Monahan 2022 Agreement between older adult patient and caregiver proxy symptom reports J Patient-Reported Outcomes 6 1 12 https://doi.org/10.1186/S41687-022-00457-8CrossRef

19.

S Schmidt M Power A Green R Lucas-Carrasco E Eser E Dragomirecka 2010 Self and proxy rating of quality of life in adults with intellectual disabilities: results from the DISQOL study Res Dev Disabil 31 1015 1026 https://doi.org/10.1016/J.RIDD.2010.04.013CrossRefPubMed

20.

CB Terwee SDM Bot MR Boer de DAWM Windt van der DL Knol J Dekker 2007 Quality criteria were proposed for measurement properties of health status questionnaires J Clin Epidemiol 60 34 42 https://doi.org/10.1016/J.JCLINEPI.2006.03.012CrossRefPubMed

21.

T Morel SJ Cano 2017 Measuring what matters to rare disease patients: reflections on the work by the IRDiRC taskforce on patient-centered outcome measures Orphanet J Rare Dis 12 1 13 https://doi.org/10.1186/S13023-017-0718-X/TABLES/7CrossRef

22.

L Rajmil L Perestelo-Pérez M Herdman 2010 Quality of life and rare diseases Adv Exp Med Biol 686 251 272 https://doi.org/10.1007/978-90-481-9485-8_15CrossRefPubMed

23.

B Wiering D Boer de D Delnoij 2017 Patient involvement in the development of patient-reported outcome measures: a scoping review Health Expect 20 11 https://doi.org/10.1111/HEX.12442CrossRefPubMed

24.

T Greenhalgh B Hurwitz 1999 Narrative based medicine: why study narrative? BMJ Br Med J 318 48 https://doi.org/10.1136/BMJ.318.7175.48CrossRef

25.

C Cardão L Barros R Francisco D Silva VR Ferreira 2021 Experiences of parents with children with congenital disorders of glycosylation: what can we learn from them? Disabil Health J https://doi.org/10.1016/J.DHJO.2021.101065CrossRefPubMed

26.

R Francisco C Pascoal D Marques-Da-silva S Brasil FM Pimentel-Santos R Altassan 2020 New insights into immunological involvement in congenital disorders of glycosylation (CDG) from a people-centric approach J Clin Med 9 2092 https://doi.org/10.3390/JCM9072092CrossRefPubMedCentral

27.

M Schiff C Roda ML Monin A Arion M Barth N Bednarek 2017 Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature J Med Genet 54 843 851 https://doi.org/10.1136/JMEDGENET-2017-104903CrossRefPubMed

28.

D Marques-da-Silva R Francisco FV Reis dos L Forbat R Lagoa PA Videira 2019 An electronic questionnaire for liver assessment in congenital disorders of glycosylation (LeQCDG): a patient-centered study JIMD Rep 44 55 64 https://doi.org/10.1007/8904_2018_121CrossRefPubMed

29.

M Serrano 2021 Stroke-like episodes in PMM2-CDG: when the lack of other evidence is the only evidence Front Pediatr 9 717864https://doi.org/10.3389/FPED.2021.717864CrossRefPubMedPubMedCentral

30.

F Pettinato G Mostile R Battini D Martinelli A Madeo E Biamino 2021 Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG) Cerebellum 20 596 https://doi.org/10.1007/S12311-021-01242-XCrossRefPubMedPubMedCentral

31.

R Francisco S Brasil C Pascoal J Jaeken M Liddle PA Videira 2022 The road to successful people-centric research in rare diseases: the web-based case study of the Immunology and Congenital Disorders of Glycosylation questionnaire (ImmunoCDGQ) Orphanet J Rare Dis 17 1 18 https://doi.org/10.1186/S13023-022-02286-W/FIGURES/5CrossRef

32.

L Turner-Stokes 2009 Goal attainment scaling (GAS) in rehabilitation: a practical guide Clin Rehabil 23 362 370 https://doi.org/10.1177/0269215508101742CrossRefPubMed

33.

AN Ligezka A Mohamed C Pascoal VDR Ferreira S Boyer C Lam 2022 Patient-reported outcomes and quality of life in PMM2-CDG Mol Genet Metab 136 145 151 https://doi.org/10.1016/J.YMGME.2022.04.002CrossRefPubMed

34.

Fayers PM, Machin D. Quality of life : the assessment, analysis, and reporting of patient-reported outcomes n.d.

35.

K Hilari S Byng 2009 Health-related quality of life in people with severe aphasia Int J Lang Commun Disord 44 193 205 https://doi.org/10.1080/13682820802008820CrossRefPubMed

36.

CB Terwee CAC Prinsen A Chiarotto MJ Westerman DL Patrick J Alonso 2018 COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study Qual Life Res 27 1159 1170 https://doi.org/10.1007/S11136-018-1829-0CrossRefPubMedPubMedCentral

37.

AI Tröster R Pahwa JA Fields CM Tanner KE Lyons 2005 Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation Parkinsonism Relat Disord 11 367 373 https://doi.org/10.1016/J.PARKRELDIS.2005.05.009CrossRefPubMed

38.

A Schrag C Selai C Mathias P Low J Hobart N Brady 2007 Measuring health-related quality of life in MSA: the MSA-QoL Mov Disord 22 2332 2338 https://doi.org/10.1002/MDS.21649CrossRefPubMed

39.

CP Green CB Porter DR Bresnahan JA Spertus 2000 Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure J Am Coll Cardiol 35 1245 1255 https://doi.org/10.1016/S0735-1097(00)00531-3CrossRefPubMed

40.

S Heo DK Moser B Riegel LA Hall N Christman 2005 Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire Nurs Res 54 265 272 https://doi.org/10.1097/00006199-200507000-00009CrossRefPubMed

41.

B Riegel DK Moser D Glaser B Carlson C Deaton R Armola 2002 The Minnesota living with heart failure questionnaire: sensitivity to differences and responsiveness to intervention intensity in a clinical population Nurs Res 51 209 218 https://doi.org/10.1097/00006199-200207000-00001CrossRefPubMed

42.

A Rentz E Flood C Altisent M Bullinger R Klamroth RP Garrido 2008 Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia Haemophilia 14 1023 1034 https://doi.org/10.1111/J.1365-2516.2008.01812.XCrossRefPubMed

43.

S Mackensen Von M Bullinger P Arranz G Auerswald J Aznar M Berg van den 2004 Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL) Haemophilia 10 Suppl 1 17 25 https://doi.org/10.1111/J.1355-0691.2004.00875.XCrossRef

44.

NL Young CS Bradley CD Wakefield D Barnard VS Blanchette PJ McCusker 2006 How well does the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer 47 305 311 https://doi.org/10.1002/PBC.20618CrossRefPubMed

45.

Yorkston KM, Bombardier C, Hammen VL. Dysarthria from the viewpoint of individuals with dysarthria. Mot Speech Disord Adv Assess Treat 1994:19–36.

46.

V Piacentini A Zuin D Cattaneo A Schindler 2011 Reliability and validity of an instrument to measure quality of life in the dysarthric speaker Folia Phoniatr Logop 63 289 295 https://doi.org/10.1159/000322800CrossRefPubMed

47.

L Hartelius M Elmberg R Holm AS Lövberg S Nikolaidis 2008 Living with dysarthria: evaluation of a self-report questionnaire Folia Phoniatr Logop 60 11 19 https://doi.org/10.1159/000111799CrossRefPubMed

48.

M Walshe RK Peach N Miller 2009 Dysarthria impact profile: development of a scale to measure psychosocial effects Int J Lang Commun Disord 44 693 715 https://doi.org/10.1080/13682820802317536CrossRefPubMed

49.

RN Rinkel IM Verdonck-de Leeuw EJ Reij Van NK Aaronson R Leemans 2008 Speech Handicap Index in patients with oral and pharyngeal cancer: better understanding of patients’ complaints Head Neck 30 868 874 https://doi.org/10.1002/HED.20795CrossRefPubMed

50.

CA McHorney DE Bricker AE Kramer JC Rosenbek JA Robbins KA Chignell 2000 The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development Dysphagia 15 115 121 https://doi.org/10.1007/S004550010012CrossRefPubMed

51.

CA McHorney D Earl Bricker J Robbins AE Kramer JC Rosenbek KA Chignell 2000 The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling Dysphagia 15 122 133 https://doi.org/10.1007/S004550010013CrossRefPubMed

52.

CA McHorney JA Robbins K Lomax JC Rosenbek K Chignell AE Kramer 2002 The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity Dysphagia 17 97 114 https://doi.org/10.1007/S00455-001-0109-1CrossRefPubMed

53.

V Woisard MP Andrieux M Puech 2006 Validation of a self-assessment questionnaire for swallowing disorders (Deglutition Handicap Index) Rev Laryngol Otol Rhinol (Bord) 127 315 325

54.

V Woisard B Lepage 2010 The, “Deglutition Handicap Index” a self-administrated dysphagia-specific quality of life questionnaire: temporal reliability Rev Laryngol 131 19 22

55.

PC Belafsky DA Mouadeb CJ Rees JC Pryor GN Postma J Allen 2008 Validity and reliability of the Eating Assessment Tool (EAT-10) Ann Otol Rhinol Laryngol 117 919 924 https://doi.org/10.1177/000348940811701210CrossRefPubMed

56.

J Wilmskoetter H Bonilha I Hong RJ Hazelwood B Martin-Harris C Velozo 2019 Construct validity of the Eating Assessment Tool (EAT-10) Disabil Rehabil 41 549 559 https://doi.org/10.1080/09638288.2017.1398787CrossRefPubMed

57.

AK Silbergleit L Schultz BH Jacobson T Beardsley AF Johnson 2012 The Dysphagia handicap index: development and validation Dysphagia 27 46 52 https://doi.org/10.1007/S00455-011-9336-2CrossRefPubMed

58.

A Dunngalvin C Cullinane DA Daly BMJ Flokstra-De Blok AEJ Dubois JB Hourihane 2010 Longitudinal validity and responsiveness of the Food Allergy Quality of Life Questionnaire—parent form in children 0–12 years following positive and negative food challenges Clin Exp Allergy 40 476 485 https://doi.org/10.1111/J.1365-2222.2010.03454.XCrossRefPubMed

59.

RK Doorn Van LMF Winkler KH Zwinderman ML Mearin HM Koopman 2008 CDDUX: a disease-specific health-related quality-of-life questionnaire for children with celiac disease J Pediatr Gastroenterol Nutr 47 147 152 https://doi.org/10.1097/MPG.0B013E31815EF87DCrossRefPubMed

60.

E Irvine Q Zhou AK Thompson 1996 The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial Am J Gastroenterol 91 1571 1578PubMed

61.

MJ Alcalá F Casellas G Fontanet L Prieto JR Malagelada 2004 Shortened questionnaire on quality of life for inflammatory bowel disease Inflamm Bowel Dis 10 383 391 https://doi.org/10.1097/00054725-200407000-00009CrossRefPubMed

62.

BA Hahn LJ Kirchdoerfer S Fullerton E Mayer 1997 Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome Aliment Pharmacol Ther 11 547 552 https://doi.org/10.1046/J.1365-2036.1997.00168.XCrossRefPubMed

63.

DL Patrick DA Drossman IO Frederick J Dicesare KL Puder 1998 Quality of life in persons with irritable bowel syndrome: development and validation of a new measure Dig Dis Sci 43 400 411 https://doi.org/10.1023/A:1018831127942CrossRefPubMed

64.

DA Drossman DL Patrick WE Whitehead BB Toner NE Diamant Y Hu 2000 Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire Am J Gastroenterol 95 999 1007 https://doi.org/10.1111/J.1572-0241.2000.01941.XCrossRefPubMed

65.

V Velanovich 2007 The development of the GERD-HRQL symptom severity instrument Dis Esophagus 20 130 134 https://doi.org/10.1111/J.1442-2050.2007.00658.XCrossRefPubMed

66.

E Eypasch JI Williams S Wood-Dauphinee BM Ure C Schmulling E Neugebauer 1995 Gastrointestinal Quality of Life Index: development, validation and application of a new instrument Br J Surg 82 216 222 https://doi.org/10.1002/BJS.1800820229CrossRefPubMed

67.

D Khanna RD Hays GS Park Y Braun-Moscovici MD Mayes TA McNearney 2007 Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument Arthritis Rheum 57 1280 1286 https://doi.org/10.1002/ART.22987CrossRefPubMed

68.

JM Blazeby T Conroy E Hammerlid P Fayers O Sezer M Koller 2003 Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer Eur J Cancer 39 1384 1394 https://doi.org/10.1016/S0959-8049(03)00270-3CrossRefPubMed

69.

AHG Davies G Larsson J Ardill E Friend L Jones M Falconi 2006 Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours Eur J Cancer 42 477 484 https://doi.org/10.1016/J.EJCA.2005.10.025CrossRefPubMed

70.

G Yadegarfar L Friend L Jones LM Plum J Ardill B Taal 2013 Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours Br J Cancer 108 301 https://doi.org/10.1038/BJC.2012.560CrossRefPubMedPubMedCentral

71.

JP Baxter PM Fayers AW McKinlay 2008 The development and translation of a treatment-specific quality of life questionnaire for adult patients on home parenteral nutrition Eur e-J Clin Nutr Metab 3 e22 e28 https://doi.org/10.1016/J.ECLNM.2007.10.001CrossRef

72.

JP Baxter PM Fayers F Bozzetti D Kelly F Joly G Wanten 2019 An international study of the quality of life of adult patients treated with home parenteral nutrition Clin Nutr 38 1788 1796 https://doi.org/10.1016/J.CLNU.2018.07.024CrossRefPubMed

73.

K Furuta S Ishihara S Sato T Miyake N Ishimura K Koshino 2019 Development and verification of the Izumo Scale, new questionnaire for quality of life assessment of patients with gastrointestinal symptoms Nihon Shokakibyo Gakkai Zasshi 106 1478 1487

74.

NJ Talley M Verlinden M Jones 2001 Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form Aliment Pharmacol Ther 15 207 216 https://doi.org/10.1046/J.1365-2036.2001.00900.XCrossRefPubMed

75.

G Guyatt A Mitchell EJ Irvine J Singer N Williams R Goodacre 1989 A new measure of health status for clinical trials in inflammatory bowel disease Gastroenterology 96 804 810CrossRefPubMed

76.

JR Love EJ Irvine RN Fedorak 1992 Quality of life in inflammatory bowel disease J Clin Gastroenterol 14 15 19 https://doi.org/10.1097/00004836-199201000-00005CrossRefPubMed

77.

C Hopkins S Gillett R Slack VJ Lund JP Browne 2009 Psychometric validity of the 22-item Sinonasal Outcome Test Clin Otolaryngol 34 447 454 https://doi.org/10.1111/J.1749-4486.2009.01995.XCrossRefPubMed

78.

JF Piccirillo MG Merritt ML Richards 2002 Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20) Otolaryngol Head Neck Surg 126 41 47 https://doi.org/10.1067/MHN.2002.121022CrossRefPubMed

79.

SS Birring B Prudon AJ Carr SJ Singh L Morgan ID Pavord 2003 Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) Thorax 58 339 343 https://doi.org/10.1136/THORAX.58.4.339CrossRefPubMedPubMedCentral

80.

TR Haher JM Gorup TM Shin P Homel AA Merola DP Grogan 1999 Results of the Scoliosis Research Society instrument for evaluation of surgical outcome in adolescent idiopathic scoliosis. A multicenter study of 244 patients Spine 24 1435 1440 https://doi.org/10.1097/00007632-199907150-00008CrossRefPubMed

81.

M Asher SM Lai D Burton B Manna 2003 The reliability and concurrent validity of the scoliosis research society-22 patient questionnaire for idiopathic scoliosis Spine 28 63 69 https://doi.org/10.1097/00007632-200301010-00015CrossRefPubMed

82.

MA Asher SM Lai RC Glattes DC Burton A Alanay J Bago 2006 Refinement of the SRS-22 health-related quality of life questionnaire function domain Spine 31 593 597 https://doi.org/10.1097/01.BRS.0000201331.50597.EACrossRefPubMed

83.

A Caronni F Zaina S Negrini 2014 Improving the measurement of health-related quality of life in adolescent with idiopathic scoliosis: the SRS-7, a Rasch-developed short form of the SRS-22 questionnaire Res Dev Disabil 35 784 799 https://doi.org/10.1016/J.RIDD.2014.01.020CrossRefPubMed

84.

J Corona H Matsumoto DP Roye MG Vitale 2011 Measuring quality of life in children with early onset scoliosis: development and initial validation of the early onset scoliosis questionnaire J Pediatr Orthop 31 180 185 https://doi.org/10.1097/BPO.0B013E3182093F9FCrossRefPubMed

85.

RJ Feise S Donaldson ER Crowther J Michael Menke JG Wright 2005 Construction and validation of the scoliosis quality of life index in adolescent idiopathic scoliosis Spine 30 1310 1315 https://doi.org/10.1097/01.BRS.0000163885.12834.CACrossRefPubMed

86.

A Caronni L Sciumè S Donzelli F Zaina S Negrini 2017 ISYQOL: a Rasch-consistent questionnaire for measuring health-related quality of life in adolescents with spinal deformities Spine J 17 1364 1372 https://doi.org/10.1016/J.SPINEE.2017.05.022CrossRefPubMed

87.

A Caronni S Donzelli F Zaina S Negrini 2019 The Italian Spine Youth Quality of Life questionnaire measures health-related quality of life of adolescents with spinal deformities better than the reference standard, the Scoliosis Research Society 22 questionnaire Clin Rehabil 33 1404 1415 https://doi.org/10.1177/0269215519842246CrossRefPubMed

88.

ZM Younossi M Stepanova L Henry A Racila B Lam HT Pham 2017 A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD Liver Int 37 1209 1218 https://doi.org/10.1111/LIV.13391/SUPPINFOCrossRefPubMed

89.

ZM Younossi M Stepanova I Younossi A Racila 2019 Validation of Chronic Liver Disease Questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 17 2093 2100.e3 https://doi.org/10.1016/J.CGH.2019.01.001CrossRefPubMed

90.

ZM Younossi G Guyatt M Kiwi N Boparai D King 1999 Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease Gut 45 295 https://doi.org/10.1136/GUT.45.2.295CrossRefPubMedPubMedCentral

91.

DA Revicki AM Rentz N Harnam VS Thomas P Lanzetta 2010 Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration Investig Ophthalmol Vis Sci 51 712 717 https://doi.org/10.1167/IOVS.09-3766CrossRef

92.

JJ Nichols GL Mitchell M Saracino K Zadnik 2003 Reliability and validity of refractive error-specific quality-of-life instruments Arch Ophthalmol 121 1289 1296 https://doi.org/10.1001/ARCHOPHT.121.9.1289CrossRefPubMed

93.

FM Costela K Pesudovs MA Sandberg C Weigel-Difranco RL Woods 2020 Validation of a vision-related activity scale for patients with retinitis pigmentosa Health Qual Life Outcomes 18 1 11 https://doi.org/10.1186/S12955-020-01427-8/FIGURES/5CrossRef

94.

SR Hatt DA Leske YS Castañeda SM Wernimont L Liebermann CS Cheng-Patel 2019 Development of pediatric eye questionnaires for children with eye conditions Am J Ophthalmol 200 201 217 https://doi.org/10.1016/J.AJO.2019.01.001CrossRefPubMedPubMedCentral

95.

SR Hatt DA Leske T Yamada EA Bradley SR Cole JM Holmes 2010 Development and initial validation of quality-of-life questionnaires for intermittent exotropia Ophthalmology https://doi.org/10.1016/J.OPHTHA.2009.06.038CrossRefPubMed

96.

SR Hatt DA Leske EA Bradley SR Cole JM Holmes 2009 Development of a quality-of-life questionnaire for adults with strabismus Ophthalmology https://doi.org/10.1016/J.OPHTHA.2008.08.043CrossRefPubMed

97.

VK Gothwal S Bharani R Kekunnaya P Chhablani V Sachdeva NK Pehere 2015 Measuring Health-Related Quality of Life in Strabismus: a modification of the adult Strabismus-20 (AS-20) Questionnaire using Rasch analysis PLoS ONE 10 e0127064https://doi.org/10.1371/JOURNAL.PONE.0127064CrossRefPubMedPubMedCentral

98.

C Owsley G McGwin K Scilley K Kallies 2006 Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy Investig Ophthalmol Vis Sci 47 528 535 https://doi.org/10.1167/IOVS.05-1222CrossRef

99.

GDB Ribeiro AGZ Bach CM Faria S Anastásia HC Almeida de 2014 Quality of life of patients with strabismus Arq Bras Oftalmol 77 110 113 https://doi.org/10.5935/0004-2749.20140027CrossRef

100.

W Maples 2000 Test-retest reliability of the College of Optometrists in Vision Development Quality of Life Outcomes Assessment Optometry 71 579 585PubMed

101.

M Kothari S Balankhe R Gawade S Toshnival 2009 Comparison of psychosocial and emotional consequences of childhood strabismus on the families from rural and urban India Indian J Ophthalmol 57 285 https://doi.org/10.4103/0301-4738.53053CrossRefPubMedPubMedCentral

102.

C Mckeon B Wick LA Aday C Begley 1997 A case-comparison of intermittent exotropia and quality of life measurements Optom Vis Sci 74 105 110 https://doi.org/10.1097/00006324-199702000-00022CrossRefPubMed

103.

T Takashima T Yokoyama S Futagami K Ohno-Matsui H Tanaka T Tokoro 2001 The quality of life in patients with pathologic myopia Jpn J Ophthalmol 45 84 92 https://doi.org/10.1016/S0021-5155(00)00305-1CrossRefPubMed

104.

ES Graaf van de J Felius H Kempen-du Saar CWN Looman J Passchier H Kelderman 2009 Construct validation of the Amblyopia and Strabismus Questionnaire (A&SQ) by factor analysis Graefe’s Arch Clin Exp Ophthalmol 247 1263 https://doi.org/10.1007/S00417-009-1112-8CrossRef

105.

K Pesudovs E Garamendi DB Elliott 2004 The Quality of Life Impact of Refractive Correction (QIRC) Questionnaire: development and validation Optom Vis Sci 81 769 777 https://doi.org/10.1097/00006324-200410000-00009CrossRefPubMed

106.

BA Raphael KM Galetta DA Jacobs CE Markowitz GT Liu ML Nano-Schiavi 2006 Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25 Am J Ophthalmol https://doi.org/10.1016/J.AJO.2006.06.060CrossRefPubMed

107.

Y Chen X Chen J Chen J Zheng J Xu X Yu 2016 Longitudinal impact on quality of life for school-aged children with amblyopia treatment: perspective from children Curr Eye Res 41 208 214 https://doi.org/10.3109/02713683.2015.1011280CrossRefPubMed

108.

MC Brown SC Schallhorn KA Hettinger SE Malady 2009 Satisfaction of 13,655 patients with laser vision correction at 1 month after surgery J Refract Surg https://doi.org/10.3928/1081597X-20090611-03CrossRefPubMed

109.

S Schallhorn M Brown J Venter K Hettinger S Hannan 2014 The role of the mesopic pupil on patient-reported outcomes in young patients with myopia 1 month after wavefront-guided LASIK J Refract Surg 30 159 165 https://doi.org/10.3928/1081597X-20140217-02CrossRefPubMed

110.

S Schallhorn M Brown J Venter D Teenan K Hettinger H Yamamoto 2014 Early clinical outcomes of wavefront-guided myopic LASIK treatments using a new-generation hartmann-shack aberrometer J Refract Surg 30 14 21 https://doi.org/10.3928/1081597X-20131029-02CrossRefPubMed

111.

RJ McLean GDE Maconachie I Gottlob J Maltby 2016 The development of a Nystagmus-Specific Quality-of-Life Questionnaire Ophthalmology 123 2023 2027 https://doi.org/10.1016/J.OPHTHA.2016.05.033CrossRefPubMed

112.

DB Erickson F Stapleton P Erickson R Toit Du E Giannakopoulos B Holden 2004 Development and validation of a multidimensional quality-of-life scale for myopia Optom Vis Sci 81 70 81 https://doi.org/10.1097/00006324-200402000-00004CrossRefPubMed

113.

X Badia L Prieto M Roset A Díez-Pérez 2000 Development of the ECOS-16 clinical questionnaire for the assessment of the quality of life in patients with osteoporosis Med Clin 114 Suppl 68 75

114.

X Badia A Díez-Pérez R Lahoz L Lizán X Nogués J Iborra 2004 The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis Health Qual Life Outcomes 2 1 11 https://doi.org/10.1186/1477-7525-2-41/FIGURES/1CrossRef

115.

SL Silverman 2000 The Osteoporosis Assessment Questionnaire (OPAQ): a reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis Qual Life Res 9 767 774CrossRef

116.

JM Chandler AR Martin C Girman PD Ross B Love-McClung E Lydick 1998 Reliability of an Osteoporosis-Targeted Quality of Life Survey Instrument for use in the community: OPTQoL Osteoporos Int 8 127 135 https://doi.org/10.1007/BF02672508CrossRefPubMed

117.

M McClung B Love C Rosen C Kessenich J Stock J Overdorf 1995 Evaluation of a new osteoporosis quality-of-life questionnaire (OQLQ) for women with osteoporosis and back pain J Bone Miner Res 10 S255

118.

DJ Cook GH Guyatt JD Adachi RS Epstein EF Juniper PA Austin 1999 Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group Osteoporos Int 10 207 213 https://doi.org/10.1007/S001980050217CrossRefPubMed

119.

C Loge de la K Sullivan R Pinkney P Marquis C Roux PJ Meunier 2005 Cross-cultural validation and analysis of responsiveness of the QUALIOST(R): QUAlity of Life questionnaire in OSTeoporosis Health Qual Life Outcomes 3 1 10 https://doi.org/10.1186/1477-7525-3-69/TABLES/5CrossRef

120.

G Baker A Jacoby 1994 Development of an instrument to assess quality of life in children with epilepsy and learning disability Epilepsia 35 S47

121.

D Buck M Smith R Appleton GA Baker A Jacoby 2007 The development and validation of the Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale Epilepsy Behav 10 38 43 https://doi.org/10.1016/J.YEBEH.2006.10.010CrossRefPubMed

122.

JA Cramer K Perrine O Devinsky K Meador 1996 A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10 Epilepsia 37 577 582 https://doi.org/10.1111/J.1528-1157.1996.TB00612.XCrossRefPubMed

123.

JA Cramer K Perrine O Devinsky L Bryant-Comstock K Meador B Hermann 1998 Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory Epilepsia 39 81 88 https://doi.org/10.1111/J.1528-1157.1998.TB01278.XCrossRefPubMed

124.

JA Cramer LE Westbrook O Devinsky K Perrine MB Glassman C Camfield 1999 Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-AD-48 Epilepsia 40 1114 1121 https://doi.org/10.1111/J.1528-1157.1999.TB00828.XCrossRefPubMed

125.

M Sabaz JA Lawson DR Cairns MS Duchowny TJ Resnick PM Dean 2003 Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients Epilepsy Behav 4 680 691 https://doi.org/10.1016/J.YEBEH.2003.08.012CrossRefPubMed

126.

SW Goodwin AI Lambrinos MA Ferro M Sabaz KN Speechley 2015 Development and assessment of a shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55) Epilepsia 56 864 872 https://doi.org/10.1111/EPI.13000CrossRefPubMed

127.

CH Bastien A Vallières CM Morin 2001 Validation of the Insomnia Severity Index as an outcome measure for insomnia research Sleep Med 2 297 307 https://doi.org/10.1016/S1389-9457(00)00065-4CrossRefPubMed

128.

Moul D, Pilkonis P, Miewald J, Carey T, DJ B. Preliminary study of the test–retest reliability and concurrent validities of the Pittsburgh Insomnia Rating Scale (PIRS). Sleep 25(Abstract Suppl 2002 2002;25:A256–247.

129.

SM Webb X Badia MJ Baarahona A Colao CJ Strasburger A Tabarin 2008 Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire Eur J Endocrinol 158 623 630 https://doi.org/10.1530/EJE-07-0762CrossRefPubMed

130.

SJ Hassan EA Weymuller 1993 Assessment of quality of life in head and neck cancer patients Head Neck 15 485 496 https://doi.org/10.1002/HED.2880150603CrossRefPubMed

131.

MS Litwin RD Hays A Fink PA Ganz B Leake RH Brook 1998 The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure Med Care 36 1002 1012 https://doi.org/10.1097/00005650-199807000-00007CrossRefPubMed

Title: Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals
Authors: C. Pascoal
I. Ferreira
C. Teixeira
E. Almeida
A. Slade
S. Brasil
R. Francisco
A. N. Ligezka
E. Morava
H. Plotkin
J. Jaeken
P. A. Videira
L. Barros
V. dos Reis Ferreira
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2022
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-022-02551-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals

Abstract

Background

Aim and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Developing a taxonomy of care coordination for people living with rare conditions: a qualitative study

Distress and post-traumatic stress in parents of patients with congenital gastrointestinal malformations: a cross-sectional cohort study

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases

Behçet’s disease in Wales: an epidemiological description of national surveillance data

Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment

Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?